Critical Analysis: Fulgent Genetics (FLGT) & Psychemedics (PMD)
Fulgent Genetics (NASDAQ:FLGT) and Psychemedics (NASDAQ:PMD) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.
Psychemedics pays an annual dividend of $0.72 per share and has a dividend yield of 4.4%. Fulgent Genetics does not pay a dividend.
This table compares Fulgent Genetics and Psychemedics’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Fulgent Genetics||$18.73 million||3.17||-$2.51 million||($0.11)||-29.91|
|Psychemedics||$39.70 million||2.27||$6.12 million||N/A||N/A|
Psychemedics has higher revenue and earnings than Fulgent Genetics.
This table compares Fulgent Genetics and Psychemedics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of current recommendations for Fulgent Genetics and Psychemedics, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Fulgent Genetics currently has a consensus target price of $5.05, suggesting a potential upside of 53.50%. Given Fulgent Genetics’ higher possible upside, research analysts plainly believe Fulgent Genetics is more favorable than Psychemedics.
Volatility and Risk
Fulgent Genetics has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500. Comparatively, Psychemedics has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500.
Institutional & Insider Ownership
8.1% of Fulgent Genetics shares are owned by institutional investors. Comparatively, 57.4% of Psychemedics shares are owned by institutional investors. 58.8% of Fulgent Genetics shares are owned by insiders. Comparatively, 8.6% of Psychemedics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Psychemedics beats Fulgent Genetics on 9 of the 13 factors compared between the two stocks.
About Fulgent Genetics
Fulgent Genetics, Inc., together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, learning software, and genetic diagnostics tools and integrated laboratory processes. The company primarily serves hospitals and medical institutions. It markets its tests through internal sales force, as well as through independent sales representatives in the United States, Canada, the People's Republic of China, and internationally. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.
Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States and internationally. The company's tests provide quantitative information that can indicate the approximate amount of drug ingested, as well as historical data, which can show a pattern of individual drug use over a longer period of time. It provides screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, PCP, amphetamines, synthetic cannabinoids, and benzodiazepines, as well as opiates, including heroin, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine. The company offers its services to employers for applicant and employee testing; treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use; and Fortune 500 companies and small to mid-size corporations, as well as school and government entities. Psychemedics Corporation was founded in 1985 and is headquartered in Acton, Massachusetts.
Receive News & Ratings for Fulgent Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulgent Genetics and related companies with MarketBeat.com's FREE daily email newsletter.